drugset / Trial / NCT01024647
Optimizing Cimzia in Crohn's Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if increasing the dose and/or dosing frequency of certolizumab pegol (Cimzia) is effective in regaining and optimizing response in patients with moderate to severe Crohn's disease.
Timeline
- Start
- 2009-12
- Primary completion
- 2013-05
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Certolizumab Pegol | Protein / enzyme biologic | 200 mg | — |
| Comparator | Certolizumab Pegol | Protein / enzyme biologic | 400 mg | — |